Eli Lilly Finally Pulls BackDrug developer Eli Lilly shot to new highs earlier in the year, and now it’s finally pulled back.
The first pattern on today’s chart is the high-volume bullish candle on May 3. The move followed positive Phase 3 data for donanemab, its potential Alzheimer's disease treatment.
Second, prices are t
